TB-500

In the analytical and regulatory sources cited here, TB-500 refers to the N-acetylated seven-residue peptide Ac-LKKTETQ, identified as the 17–23 fragment of thymosin beta-4 (Tβ4).

That description is not the same as full-length Tβ4, which is a 43-residue peptide. The two materials differ in length and composition; findings about the full-length peptide must not be silently attributed to the short fragment. Because the name TB-500 is also used inconsistently in secondary material, read the exact sequence, terminal modification, and analytical characterization in the source at hand.

The illustration deliberately separates a short fragment motif from a longer chain as an identity metaphor. It is not an experimentally resolved structure, a scale drawing, or evidence of biological activity.

The sources assembled for this file establish an analytical identity and detection record; they do not establish a specific receptor, binding event, or complete TB-500 signaling pathway.

A short fragment's relationship to a longer parent sequence is a sequence fact, not proof that the fragment reproduces every property attributed to the parent molecule. For TB-500 specifically, the cited analytical reports focus on identifying and characterizing the material, rather than demonstrating a confirmed receptor interaction or downstream biological cascade.

The artwork uses open branches and unresolved nodes to mark questions rather than answers. Treat any proposed target or pathway as unconfirmed unless a TB-500-specific experiment directly tests and reports it.

• Verify which exact material an experiment used
• Separate sequence relationship from functional equivalence
• Require direct evidence before assigning a target or pathway

A central TB-500-specific record is analytical: researchers synthesized or characterized the peptide and developed mass-spectrometric methods to identify it and related metabolites.

Ho and colleagues reported liquid chromatography–mass spectrometry analysis of TB-500 in equine urine and plasma. Esposito and colleagues reported synthesis and characterization of the N-terminal acetylated 17–23 fragment identified in material marketed as TB-500. These papers address chemical identity and analytical detection; they should not be presented as efficacy studies.

For each report, check the sample matrix, synthesis or reference material, analytical method, identification criteria, and stated limitations. An analytical signal establishes what the method identified in that context; it does not by itself establish a biological mechanism or outcome.

• Ho et al. (2012): LC-MS analysis in equine sample matrices
• Esposito et al. (2012): synthesis and characterization of Ac-LKKTETQ
• WADA resource: in-vitro/ex-vivo metabolism and synthesis context

TB-500 and full-length thymosin beta-4 should be treated as distinct research materials unless a study directly compares the exact constructs under defined conditions.

TB-500 is described in the cited identity sources as Ac-LKKTETQ, a seven-residue fragment corresponding to Tβ4 residues 17–23. Full-length Tβ4 is a 43-residue peptide. Shared sequence origin does not establish interchangeable structure, binding, signaling, metabolism, or experimental behavior.

The cited analytical characterization and detection studies answer a different question from a functional comparison. They do not establish that the fragment reproduces a pathway assigned to full-length Tβ4, nor do they establish a direct comparative biological effect. Keep each material, method, model, and endpoint in its own evidence column.

• Short N-acetylated fragment versus 43-residue full-length peptide
• Analytical identification versus functional testing
• Do not transfer parent-peptide mechanisms without direct fragment evidence

Bottom line: the source set supports a defined chemical identity and analytical research record for TB-500; it does not support broad claims about a verified target, complete mechanism, or biological outcome.

The most directly applicable records here concern composition, synthesis, mass-spectrometric identification, and metabolism-related analytical work. Those are valuable evidence categories, but they are not substitutes for TB-500-specific functional studies. Claims based on full-length thymosin beta-4, another fragment, or a different preparation must remain attributed to that separate material.

Open questions include how different preparations are defined across sources and what biological effects, if any, are directly demonstrated for the exact acetylated heptapeptide in specific experimental systems. The visual marks these boundaries as unresolved. Consult each source's methods and scope; do not infer more than the reported material and measurements support.

• Identity and analytical detection are not efficacy evidence
• Name ambiguity makes sequence and modification verification important
• No specific receptor or complete pathway is asserted by this page